- Which drugs should post-MI patients routinely receive? The Journal.
- Top Cardiologist Argues We Should Dial Back On Statins Because.
- Lipitor New FDA Drug Approval CenterWatch
- The Anglo-Scandinavian Cardiac Outcomes Trial 11-year mortality.
Which drugs should post-MI patients routinely receive? The Journal.
Ix years ago, the airwaves were alive with Lipitor ads. This means most of the people in the study died, so a 33 percent reduction in risk is huge. So what’s the problem, then, with the 36 percent reduction in risk found in the Lipitor study?
Top Cardiologist Argues We Should Dial Back On Statins Because.
Lipitor, a statin and the largest selling drug in the world at that time, was being challenged by other less expensive statins that had gone off patent, so Pfizer, the manufacturer, was blanketing the media in an effort to keep sales humming. Robert Jarvik, one of the developers of the first artificial heart. And why shouldn’t people be begging to go on Lipitor?
Lipitor New FDA Drug Approval CenterWatch
Founder and currently Executive Editor of Science-Based Medicine Steven Novella, MD is an academic clinical neurologist at the Yale University School of Medicine.
The Anglo-Scandinavian Cardiac Outcomes Trial 11-year mortality.
Lipitor (atorvastatin calcium) is a synthetic lipid-lowering agent.LIPITOR VS. SIMVASTATIN FOR EFFICACY OF.
Lipitor mortality rate:
Rating: 90 / 100
Overall: 95 Rates